174 related articles for article (PubMed ID: 31356678)
1. Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.
Guo Y; Lucksiri A; Dickinson GL; Vuppalanchi RK; Hilligoss JK; Hall SD
Clin Pharmacol Ther; 2020 Jan; 107(1):246-256. PubMed ID: 31356678
[TBL] [Abstract][Full Text] [Related]
2. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
3. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
4. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
Ogasawara A; Kume T; Kazama E
Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
[TBL] [Abstract][Full Text] [Related]
7. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
8. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
10. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
11. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
Allqvist A; Miura J; Bertilsson L; Mirghani RA
Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
[TBL] [Abstract][Full Text] [Related]
14. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
Zhang X; Quinney SK; Gorski JC; Jones DR; Hall SD
Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
[TBL] [Abstract][Full Text] [Related]
15. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
16. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Seng KY; Hee KH; Soon GH; Sapari NS; Soong R; Goh BC; Lee LS
J Clin Pharmacol; 2014 Feb; 54(2):215-24. PubMed ID: 24214410
[TBL] [Abstract][Full Text] [Related]
18. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.
Kuroha M; Azumano A; Kuze Y; Shimoda M; Kokue E
Drug Metab Dispos; 2002 Jan; 30(1):63-8. PubMed ID: 11744613
[TBL] [Abstract][Full Text] [Related]
19. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
Han B; Mao J; Chien JY; Hall SD
Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
[TBL] [Abstract][Full Text] [Related]
20. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
